http://www.fpnotebook.com/
Urge IncontinenceAka: Detrussor Instability, Overactive Bladder
- Mechanism
- PVC: "Premature Vesicular Contraction"
- Dial (2003) AAFP Board Review, Seattle
- Overly sensitive bladder
- Urge to void is perceived
- Inhibition of detrussor contraction is ineffective
- Detrussor hyperactivity
- Epidemiology
- Most common Urinary Incontinence in elderly (70%)
- Etiologies:
- Neurologic
- Stroke
- Demyelinating disease
- Local Irritation
- Urinary Tract Infection
- Bladder tumor
- Idiopathic (most common)
- Signs and Symptoms
- Irresistable urge to void
- Urge preceeded by various stimulation
- Posture change
- Hear or feel water
- Laugh or cough
- Urine volume lost
- Few drops to entire bladder contents
- Urine loss timing
- Begins seconds after trigger
- Continues beyond trigger while detrussor contracts
- Low FSV and low bladder capacity
- See Bladder Stress Test
- Diagnostics
- Post-Void Residual normal (<100 cc)
- Sterile in-out catheterization or
- Ultrasound measurement of post-void residual
- Cystoscopy indications
- Hematuria
- Recurrent Urinary Tract Infection
- Bladder Cancer risk factors
- Associated Conditions: Overactive Bladder
- Urinary urgency, frequency, nocturia and Incontinence
- May be caused by Benign Prostatic Hyperplasia
- Treatment is similar to urge Incontinence below
- Ouslander (2004) N Engl J Med 350:786
- Management: General
- General measures
- Avoid Diuretics including caffeine
- Avoid Constipation
- Plan fluid intake to prevent sleep interruption
- Behavioral measures (first-line treatment)
- See Bladder Retraining Drills
- See Kegel Exercises
- Behavioral therapy is more effective then medication
- Burgio (2002) JAMA 288:2293
- Wyman (1991) Urol Nurs 11:11
- Management: Medications
- General
- Medications are only an adjunct to behavioral therapy
- Anticholinergic (Propantheline, Imipramine)
- Inhibits detrussor contraction
- Increases bladder capacity
- Bladder Relaxants (antimuscarinics)
- See Bladder Antispasmodics
- Inhibits involuntary detrusor contractions
- Medications (long-acting agents are preferred)
- Oxybutinin XR reduces Incontinence episodes 28%
- Tolterodine XR offers similar benefit to Oxybutinin
- Oxytrol (transdermal antispasmodic patch)
- M3 Specific antimuscarinics (Vesicare, Enablex)
- Consider alpha-blocker medications if BPH present
- Example: Terazosin (Hytrin)
- Estrogen not recommended
- Oral Estrogen Replacement may exacerbate Incontinence
- Intravaginal preparations lack evidence to support
- Management: Implanted Electrical Stimulation Device
- Severe and refractory urge Incontinence
- Generator implanted in buttocks or low back
- Lead placed in sacral foramen into S3 Nerve
- Inhibits detrusor muscle contractions
- Expensive: $10,000 for device; $10,000 for surgery
- Highly effective
- Amundsen (2002) Am J Obstet Gynecol 187:1462
- References
- Appell (2001) Mayo Clin Proc 76:358
- Weiss (2005) Am Fam Physician 71:315
Navigation Tree